In what could mark a historic shift in the treatment of inherited blood disorders, the first patient to undergo Zynteglo—a gene therapy developed for beta-thalassemia—has emerged pain-free and full of life. This breakthrough not only represents hope for thousands living with the disease but also highlights the remarkable strides made in gene therapy and genetic medicine.
The Long Journey to a “Cure”
Beta-thalassemia is a severe, inherited blood disorder that reduces the body’s ability to produce hemoglobin, the oxygen-carrying protein in red blood cells. Patients like 12-year-old Rahemeen Nabeel previously faced lifelong health challenges, including chronic fatigue, pain, and dependency on regular blood transfusions to survive.
“For years, we searched for something—anything—that could give our daughter a normal life,” said Zainab Nabeel, Rahemeen’s mother. Speaking to CBS News, she recounted the family’s extensive travels across Europe and Asia in search of a cure. “We took her to Paris, Italy, Rome, Switzerland, Turkey, and Korea. It was a long, stressful journey, but we are really, really happy today.”
That happiness comes from their recent experience at the Children’s Hospital of Philadelphia (CHOP), where Rahemeen became one of the first patients to receive Zynteglo, a gene therapy approved by the U.S. Food and Drug Administration. Developed with the latest advancements in gene-editing technologies, Zynteglo works by using the patient’s own stem cells, which are genetically modified to produce functional hemoglobin, effectively correcting the genetic defect.
A Rigorous but Rewarding Process
Before receiving the therapy, Rahemeen underwent chemotherapy—a necessary but grueling step to prepare her body for the infusion of genetically modified cells. Chemotherapy temporarily wipes out the patient’s bone marrow to make room for the new, corrected cells to take hold and begin producing healthy red blood cells.
“She lost all her hair and had to endure even more pain,” Dr. Timothy Olson of CHOP shared. “But on the other side of that process, I can confidently say Rahemeen is cured.”
Dr. Olson, who oversees gene therapy treatments at CHOP, has 17 other patients in various stages of treatment. “To see a therapy like this move into being widely available for patients—this is why we do what we do,” he emphasized.
Rahemeen herself described her new life as almost “too energized.” No longer needing blood transfusions, and freed from the debilitating fatigue and pain, she can now participate in everyday activities that were previously impossible.
Beyond Traditional Treatments
Until now, the only long-term cure for beta-thalassemia was a bone marrow transplant, a procedure that comes with significant risks and is limited to those who can find a perfectly matched donor—usually a close family member. This option is inaccessible for the majority of patients due to donor scarcity and the risk of life-threatening complications, including graft-versus-host disease.
Zynteglo, by contrast, uses the patient’s own cells, eliminating the risk of donor rejection. The therapy employs scientific methods inspired by the groundbreaking work of Nobel Prize-winning biologist Shinya Yamanaka, who discovered how to transform ordinary cells into pluripotent stem cells—cells capable of becoming virtually any cell type in the body. These so-called “Yamanaka factors” form the basis of many cutting-edge therapies, including Zynteglo, which reprograms stem cells to produce healthy hemoglobin.
The Future of Gene Therapy
While Rahemeen’s case represents a medical milestone, experts caution that gene therapies like Zynteglo are not without their challenges. The therapy is complex and costly, with treatment prices reported to reach over $2 million. Access and affordability remain significant barriers, especially in low- and middle-income countries where beta-thalassemia is more prevalent.
Despite these hurdles, Dr. Olson and his team remain optimistic. “We are entering a new era where genetic diseases once thought to be incurable are now being treated at the root cause,” he said. “This is just the beginning.”
As more patients undergo treatment and more data become available, medical experts hope that regulatory bodies, insurers, and healthcare systems will work together to make these life-changing therapies accessible to all who need them.
For families like the Nabeels, the impact is already clear. “We just wanted our daughter to live a normal life,” Zainab Nabeel said. “Thanks to this treatment, she can finally do that.”
Recommended For You
